Coronavirus disease 2019 (COVID-19) has rapidly affected mortality worldwide 1 . There is
unprecedented urgency to understand who is most at risk of severe outcomes, and this …

… Elizabeth J Williamson, # 2 Alex J Walker, # 1 Krishnan Bhaskaran, # 2 Seb Bacon, # 1
Chris Bates, # 3 Caroline E Morton, 1 Helen J Curtis, 1 Amir Mehrkar, 1 David Evans, 1 …

Background COVID-19 has disproportionately affected minority ethnic populations in the UK.
Our aim was to quantify ethnic differences in SARS-CoV-2 infection and COVID-19 …

Background Establishing who is at risk from a novel rapidly arising cause of death, and why,
requires a new approach to epidemiological research with very large datasets and timely …

Background Early descriptions of patients admitted to hospital during the COVID-19 pandemic
showed a lower prevalence of asthma and chronic obstructive pulmonary disease (COPD…

Background Failure to report the results of a clinical trial can distort the evidence base for
clinical practice, breaches researchers' ethical obligations to participants, and represents an …

Background The risk of severe COVID-19 outcomes in people with immune-mediated
inflammatory diseases and on immune-modifying drugs might not be fully mediated by …

Objectives To ascertain compliance rates with the European Commission’s requirement that
all trials on the EU Clinical Trials Register (EUCTR) post results to the registry within 12 …

Objectives To assess the association between routinely prescribed non-steroidal anti-inflammatory
drugs (NSAIDs) and deaths from COVID-19 using OpenSAFELY, a secure analytical …

Background Long COVID describes new or persistent symptoms at least 4 weeks after onset
of acute COVID-19. Clinical codes to describe this phenomenon were recently created. Aim …